Nanoparticle Formulation of Oral Paclitaxel
Louisiana State University AgCenter, LA, United States
This invention is a novel nanoparticle formulation that utilizes natural plant derivatives to increase the solubility and permeability of paclitaxel and allow for oral administration. The derivatives replace harmful chemical and synthetic solvents normally required for paclitaxel to be absorbed and can potentially reduce the side effects of drug treatment.
Primary Application Area: Pharmaceuticals & Personal Care
Technology Development Status: Prototype
Technology Readiness Level: TRL 3
FIGURES OF MERIT
Value Proposition: This invention delivers a more permeable and bioavailable paclitaxel drug to treat major forms of cancer, such as breast cancer, formed with all-natural components. This could reduce the number and severity of side effects felt by cancer patients during treatment and allow for preventive and curative paclitaxel treatment.
Organization Type: Academic/Gov Lab
Showcase Booth #: 328
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date: This invention received an NIH grant.
Primary Sources of Funding: Federal Grant, University
Looking for: Both Funding and Development Partners